NovaVive Inc. Hires a Senior Vice-President, U.S. Sales & Marketing
NovaVive is pleased to welcome Robert (Bob) Barclay as Senior Vice-President, U.S. Sales & Marketing effective January 1, 2018. Bob has several years of experience in animal health, including 11 years with Zoetis Inc.
Iowa State University College of Veterinary Medicine to Conduct a Study with Immunocidin® Equine in Two Types of Cancer
NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.
Settle®, an Antibiotic Alternative for Treating Equine Endometritis, is Now Approved for Sale in New Zealand
NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.
MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle
NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.
NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).